JP2010526822A - ベンゾジアゼピン類の経鼻投与 - Google Patents

ベンゾジアゼピン類の経鼻投与 Download PDF

Info

Publication number
JP2010526822A
JP2010526822A JP2010507633A JP2010507633A JP2010526822A JP 2010526822 A JP2010526822 A JP 2010526822A JP 2010507633 A JP2010507633 A JP 2010507633A JP 2010507633 A JP2010507633 A JP 2010507633A JP 2010526822 A JP2010526822 A JP 2010526822A
Authority
JP
Japan
Prior art keywords
benzodiazepine
composition
particles
particle size
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010507633A
Other languages
English (en)
Japanese (ja)
Inventor
カルツ,スティーブ
メディーロス,デイビッド
Original Assignee
クエスター ファーマシューティカルズ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クエスター ファーマシューティカルズ,インク. filed Critical クエスター ファーマシューティカルズ,インク.
Publication of JP2010526822A publication Critical patent/JP2010526822A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2010507633A 2007-05-07 2008-05-07 ベンゾジアゼピン類の経鼻投与 Pending JP2010526822A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91655007P 2007-05-07 2007-05-07
PCT/US2008/062961 WO2008137960A1 (en) 2007-05-07 2008-05-07 Nasal administration of benzodiazepines

Publications (1)

Publication Number Publication Date
JP2010526822A true JP2010526822A (ja) 2010-08-05

Family

ID=39944024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010507633A Pending JP2010526822A (ja) 2007-05-07 2008-05-07 ベンゾジアゼピン類の経鼻投与

Country Status (5)

Country Link
US (1) US20080279784A1 (US20080279784A1-20081113-C00008.png)
EP (1) EP2152274A4 (US20080279784A1-20081113-C00008.png)
JP (1) JP2010526822A (US20080279784A1-20081113-C00008.png)
CA (1) CA2723470C (US20080279784A1-20081113-C00008.png)
WO (1) WO2008137960A1 (US20080279784A1-20081113-C00008.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016117681A (ja) * 2014-12-19 2016-06-30 積水化学工業株式会社 コアシェル構造体を含有する製剤
JP2021154135A (ja) * 2016-12-09 2021-10-07 アレクザ・ファーマシューティカルズ・インコーポレイテッドAlexza Pharmaceuticals, Inc. てんかんを処置する方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CN101842079B (zh) * 2007-08-31 2012-09-05 阿基米德开发有限公司 非水性药物组合物
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
GB201007290D0 (en) * 2010-04-30 2010-06-16 R5 Pharmaceuticals Ltd Pharmaceutical powder compositions
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
EP3415139B8 (en) * 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
CN104490893B (zh) * 2014-12-02 2016-01-06 美亚药业海安有限公司 一种治疗失眠的药物组合物
BR112023002926A2 (pt) * 2020-08-26 2023-04-25 Cila Therapeutic Inc Agentes terapêuticos inaláveis
EP4039258A1 (en) * 2021-02-08 2022-08-10 Assistance Publique, Hopitaux De Paris Use of diazepam as only tolerated benzodiazepine receptor agonist in covid-19 patients

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505403A (ja) * 1999-07-26 2003-02-12 エス ケー コーポレイション 経鼻抗痙攣組成物及び調節方法
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
WO2005089768A1 (en) * 2004-03-17 2005-09-29 University Of Kentucky Research Foundation Intranasal benzodiazepine compositions
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
WO2006088894A2 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
JP2007510722A (ja) * 2003-11-05 2007-04-26 エラン ファーマ インターナショナル リミテッド 表面安定剤としてペプチドを有するナノ粒子組成物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102116A (en) * 1963-08-27 Process for the purification of y-chloeo-
US3109843A (en) * 1963-11-05 Process for preparing
US3136815A (en) * 1959-12-10 1964-06-09 Hoffmann La Roche Amino substituted benzophenone oximes and derivatives thereof
US3371085A (en) * 1959-12-10 1968-02-27 Hoffmann La Roche 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones
US3340253A (en) * 1962-11-28 1967-09-05 Hoffmann La Roche Preparation of certain benzodiazepine compounds
US3243427A (en) * 1962-06-21 1966-03-29 Hoffmann La Roche Certain 5-phenyl-1, 2-dihydro (or 1, 2, 4, 5-tetrahydro)-3h-1, 4,-benzodiazepine compounds and their production
US3374225A (en) * 1963-03-28 1968-03-19 Hoffmann La Roche Aminobenzodiazepine compounds and methods
US3567710A (en) * 1968-06-03 1971-03-02 Hoffmann La Roche Process for the preparation of 1,3-dihydro-2h-1,4-benzodiazepin-2-ones
US3609145A (en) * 1969-01-10 1971-09-28 Upjohn Co 1h-1,4-benzodiazepine-1-sulfonamides
US3722371A (en) * 1970-03-12 1973-03-27 Pneumo Dynamics Corp High ratio linkage mechanism
US4280957A (en) * 1974-09-11 1981-07-28 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5457100A (en) * 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5661130A (en) * 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5831089A (en) * 1996-07-01 1998-11-03 Pharmacia & Upjohn Company Process to produce midazolam
ATE219355T1 (de) * 1997-02-05 2002-07-15 Jago Res Ag Medizinische aerosolformulierungen
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001051030A1 (en) * 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US7171965B2 (en) * 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
AU2003230692A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20110257096A1 (en) * 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CA2756690C (en) * 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
EP3415139B8 (en) * 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505403A (ja) * 1999-07-26 2003-02-12 エス ケー コーポレイション 経鼻抗痙攣組成物及び調節方法
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
JP2007510722A (ja) * 2003-11-05 2007-04-26 エラン ファーマ インターナショナル リミテッド 表面安定剤としてペプチドを有するナノ粒子組成物
WO2005089768A1 (en) * 2004-03-17 2005-09-29 University Of Kentucky Research Foundation Intranasal benzodiazepine compositions
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
WO2006088894A2 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016117681A (ja) * 2014-12-19 2016-06-30 積水化学工業株式会社 コアシェル構造体を含有する製剤
JP2021154135A (ja) * 2016-12-09 2021-10-07 アレクザ・ファーマシューティカルズ・インコーポレイテッドAlexza Pharmaceuticals, Inc. てんかんを処置する方法
JP7376532B2 (ja) 2016-12-09 2023-11-08 アレクザ・ファーマシューティカルズ・インコーポレイテッド てんかんを処置する方法

Also Published As

Publication number Publication date
CA2723470A1 (en) 2008-11-13
US20080279784A1 (en) 2008-11-13
EP2152274A4 (en) 2010-07-21
EP2152274A1 (en) 2010-02-17
CA2723470C (en) 2013-12-03
WO2008137960A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
US8530463B2 (en) Multimodal particulate formulations
CA2723470C (en) Nasal administration of benzodiazepines
JP6883918B2 (ja) ベンゾジアゼピン組成物の投与
AU2006214443B2 (en) Aerosol and injectable formulations of nanoparticulate benzodiazepine
EP1589947B1 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
JP5613657B2 (ja) ベンゾジアゼピン組成物の投与
JP2010513449A (ja) サブミクロン粒子に基づく治療活性物質の経粘膜送達のための医薬組成物
Hamishehkar et al. Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules
JP2006503865A (ja) 吸入のための徐放性の多孔性微粒子
JP2002531492A (ja) ナノ粒子状コア/シェル系、ならびに医薬品および化粧品におけるその使用
JP2007505831A (ja) 肺吸入による、早漏を治療するための医薬品組成物
Faghihi et al. Formulation and evaluation of inhalable microparticles of Rizatriptan Benzoate processed by spray freeze-drying
JP2006522785A (ja) アポモルヒネを含む肺吸入用医薬組成物
US8710028B2 (en) Pharmaceutical powder compositions
EP3212212B1 (en) Powder formulation
AU2011218610A1 (en) Aerosol and injectable formulations of nanoparticulate benzodiazepine

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130322

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130709